The epidemiology and molecular mechanisms linking obesity, diabetes, and cancer

Vitamins and Hormones

Volumn 93, Issue , 2013, Pages 51-98

  Ferguson, Rosalyn D ^a   Gallagher, Emily J ^a   Scheinman, Eyal J ^b   Damouni, Rawan ^b   LeRoith, Derek ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Cancer; Cholesterol; Diabetes; Insulin; Insulin like growth factor 1; Obesity

Indexed keywords

EID: 84880275831     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-416673-8.00010-1     Document Type: Chapter

References (283)

1. Accili D., Drago J., Lee E.J., Johnson M.D., Cool M.H., Salvatore P., et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nature Genetics 1996, 12:106-109.
2. Agarwal V.R., Bulun S.E., Leitch M., Rohrich R., Simpson E.R. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. The Journal of Clinical Endocrinology and Metabolism 1996, 81:3843-3849.
3. Alessi D.R., James S.R., Downes C.P., Holmes A.B., Gaffney P.R., Reese C.B., et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Current Biology 1997, 7:261-269.
4. Alikhani N., Ferguson R.D., Novosyadlyy R., Gallagher E.J., Scheinman E.J., Yakar S., et al. Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene 2013, 32:961-967.
5. Alimova I.N., Liu B.L., Fan Z.Y., Edgerton S.M., Dillon T., Lind S.E., et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009, 8:909-915.
6. Ariazi E.A., Leitao A., Oprea T.I., Chen B., Louis T., Bertucci A.M., et al. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Molecular Cancer Therapeutics 2007, 6:2817-2827.
7. Ashcroft F.M., Rorsman P. Electrophysiology of the pancreatic beta-cell. Progress in Biophysics and Molecular Biology 1989, 54:87-143.
8. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet 2005, 366:1267-1278.
9. Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: Quantification of individual receptor species by selective immunoprecipitation and immunoblotting. The Biochemical Journal 1997, 327(Pt 1):209-215.
10. Bartella V., De Marco P., Malaguarnera R., Belfiore A., Maggiolini M. New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer. Cellular Signalling 2012, 24:1515-1521.
11. Batty G.D., Kivimaki M., Clarke R., Davey Smith G., Shipley M.J. Modifiable risk factors for prostate cancer mortality in London: Forty years of follow-up in the Whitehall study. Cancer Causes & Control 2011, 22:311-318.
12. Benecke H., Flier J.S., Moller D.E. Alternatively spliced variants of the insulin receptor protein. Expression in normal and diabetic human tissues. The Journal of Clinical Investigation 1992, 89:2066-2070.
13. Benyoucef S., Surinya K.H., Hadaschik D., Siddle K. Characterization of insulin/IGF hybrid receptors: Contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. The Biochemical Journal 2007, 403:603-613.
14. Berggreen C., Gormand A., Omar B., Degerman E., Goransson O. Protein kinase B activity is required for the effects of insulin on lipid metabolism in adipocytes. American Journal of Physiology. Endocrinology and Metabolism 2009, 296:E635-E646.
15. Bergstrom A., Pisani P., Tenet V., Wolk A., Adami H.O. Overweight as an avoidable cause of cancer in Europe. International Journal of Cancer 2001, 91:421-430.
16. Berstein L.M., Boyarkina M.P., Tsyrlina E.V., Turkevich E.A., Semiglazov V.F. More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. Medical Oncology 2011, 28:1260-1263.
17. Bielecka-Dabrowa A., Hannam S., Rysz J., Banach M. Malignancy-associated dyslipidemia. The Open Cardiovascular Medicine Journal 2011, 5:35-40.
18. Bikman B.T., Zheng D., Kane D.A., Anderson E.J., Woodlief T.L., Price J.W., et al. Metformin improves insulin signaling in obese rats via reduced IKKbeta action in a fiber-type specific manner. Journal of Obesity, 2010 2010, 1-8.
19. Bo S., Ciccone G., Rosato R., Villois P., Appendino G., Ghigo E., et al. Cancer mortality reduction and metformin: A retrospective cohort study in type 2 diabetic patients. Diabetes, Obesity & Metabolism 2012, 14:23-29.
20. Bodmer M., Meier C., Krahenbuhl S., Jick S.S., Meier C.R. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010, 33:1304-1308.
21. Bonovas S., Filioussi K., Sitaras N.M. Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. International Journal of Cancer 2008, 123:899-904.
22. Bosetti C., Rosato V., Polesel J., Levi F., Talamini R., Montella M., et al. Diabetes mellitus and cancer risk in a network of case-control studies. Nutrition and Cancer 2012, 64:643-651.
23. Bowker S.L., Majumdar S.R., Veugelers P., Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29:254-258.
24. Bowker S.L., Richardson K., Marra C.A., Johnson J.A. Risk of breast cancer after onset of type 2 diabetes: Evidence of detection bias in postmenopausal women. Diabetes Care 2011, 34:2542-2544.
25. Broitman S.A., Cerda S., Wilkinson J.T. Cholesterol metabolism and colon cancer. Progress in Food & Nutrition Science 1993, 17:1-40.
26. Brown K.A., Hunger N.I., Docanto M., Simpson E.R. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Research and Treatment 2010, 123:591-596.
27. Brown K.A., McInnes K.J., Hunger N.I., Oakhill J.S., Steinberg G.R., Simpson E.R. Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women. Cancer Research 2009, 69:5392-5399.
28. Browning D.R., Martin R.M. Statins and risk of cancer: A systematic review and metaanalysis. International Journal of Cancer 2007, 120:833-843.
29. Byrnes K., White S., Chu Q., Meschonat C., Yu H., Johnson L.W., et al. High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Annals of Surgery 2006, 243:684-690. (discussion 691-692).
30. Calle E.E., Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nature Reviews. Cancer 2004, 4:579-591.
31. Cariou B., Charbonnel B., Staels B. Thiazolidinediones and PPAR gamma agonists: Time for a reassessment. Trends in Endocrinology and Metabolism 2012, 23:205-215.
32. Carstensen B., Witte D.R., Friis S. Cancer occurrence in Danish diabetic patients: Duration and insulin effects. Diabetologia 2012, 55:948-958.
33. Caruso M.G., Notarnicola M., Cavallini A., Di Leo A. 3-Hydroxy-3-methylglutaryl coenzyme A reductase activity and low-density lipoprotein receptor expression in diffuse-type and intestinal-type human gastric cancer. Journal of Gastroenterology 2002, 37:504-508.
34. Caruso M.G., Notarnicola M., Santillo M., Cavallini A., Di Leo A. Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor. Anticancer Research 1999, 19:451-454.
35. Casa A.J., Potter A.S., Malik S., Lazard Z., Kuiatse I., Kim H.T., et al. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Research and Treatment 2012, 132:61-73.
36. Caton P.W., Nayuni N.K., Kieswich J., Khan N.Q., Yaqoob M.M., Corder R. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. The Journal of Endocrinology 2010, 205:97-106.
37. Chapman H.A., Hibbs J.B. Modulation of macrophage tumoricidal capability by components of normal serum: A central role for lipid. Science 1977, 197:282-285.
38. Chen W.W., Shao Y.Y., Shau W.Y., Lin Z.Z., Lu Y.S., Chen H.M., et al. The impact of diabetes mellitus on prognosis of early breast cancer in Asia. The Oncologist 2012, 17:485-491.
39. Chlebowski R.T., McTiernan A., Wactawski-Wende J., Manson J.E., Aragaki A.K., Rohan T., et al. Diabetes, metformin, and breast cancer in postmenopausal women. Journal of Clinical Oncology 2012, 30:2844-2852.
40. Chong Y.M., Williams S.L., Elkak A., Sharma A.K., Mokbel K. Insulin-like growth factor 1 (IGF-1) and its receptor mRNA levels in breast cancer and adjacent non-neoplastic tissue. Anticancer Research 2006, 26:167-173.
41. Cleveland R.J., North K.E., Stevens J., Teitelbaum S.L., Neugut A.I., Gammon M.D. The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project. Cancer Causes & Control 2012, 23:1193-1203.
42. Colhoun H.M., Group S.E. Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009, 52:1755-1765.
43. Colmers I.N., Bowker S.L., Majumdar S.R., Johnson J.A. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: A meta-analysis. CMAJ 2012, 184:E675-E683.
44. Cruse J.P., Lewin M.R., Clark C.G. Dietary cholesterol deprivation improves survival and reduces incidence of metastatic colon cancer in dimethylhydrazine-pretreated rats. Gut 1982, 23:594-599.
45. Cui X., Zhang P., Deng W., Oesterreich S., Lu Y., Mills G.B., et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: Progesterone receptor as a potential indicator of growth factor activity in breast cancer. Molecular Endocrinology 2003, 17:575-588.
46. Currie C.J. The longest ever randomised controlled trial of insulin glargine: Study design and HbA(1c) findings. Diabetologia 2009, 52:2234-2235. (author reply 2236-2239).
47. Currie C.J., Poole C.D., Gale E.A.M. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52:1766-1777.
48. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., White C.M. Statins and cancer risk: A meta-analysis. JAMA: The Journal of the American Medical Association 2006, 295:74-80.
49. Daniels S.R., Greer F.R. Lipid screening and cardiovascular health in childhood. Pediatrics 2008, 122:198-208.
50. DeCensi A., Puntoni M., Goodwin P., Cazzaniga M., Gennari A., Bonanni B., et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prevention Research (Philadelphia, PA) 2010, 3:1451-1461.
51. Dessi S., Batetta B., Anchisi C., Pani P., Costelli P., Tessitore L., et al. Cholesterol metabolism during the growth of a rat ascites hepatoma (Yoshida AH-130). British Journal of Cancer 1992, 66:787-793.
52. Dessi S., Batetta B., Pulisci D., Spano O., Anchisi C., Tessitore L., et al. Cholesterol content in tumor tissues is inversely associated with high-density lipoprotein cholesterol in serum in patients with gastrointestinal cancer. Cancer 1994, 73:253-258.
53. Dessi S., Batetta B., Pulisci D., Spano O., Cherchi R., Lanfranco G., et al. Altered pattern of lipid metabolism in patients with lung cancer. Oncology 1992, 49:436-441.
54. Di Cristofano A., Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell 2000, 100:387-390.
55. Di Vizio D., Solomon K.R., Freeman M.R. Cholesterol and cholesterol-rich membranes in prostate cancer: An update. Tumori 2008, 94:633-639.
56. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005, 366:1279-1289.
57. Dowling R.J.O., Zakikhani M., Fantus I.G., Pollak M., Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Research 2007, 67:10804-10812.
58. Drury S.C., Detre S., Leary A., Salter J., Reis-Filho J., Barbashina V., et al. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocrine-Related Cancer 2011, 18:565-577.
59. Duggan C., Irwin M.L., Xiao L., Henderson K.D., Smith A.W., Baumgartner R.N., et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. Journal of Clinical Oncology 2011, 29:32-39.
60. Edgerton D.S., Johnson K.M.S., Cherrington A.D. Current strategies for the inhibition of hepatic glucose production in type 2 diabetes. Frontiers in Bioscience 2009, 14:1169-1181.
61. Elstner E., Muller C., Koshizuka K., Williamson E.A., Park D., Asou H., et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:8806-8811.
62. Espelund U., Cold S., Frystyk J., Orskov H., Flyvbjerg A. Elevated free IGF2 levels in localized, early-stage breast cancer in women. European Journal of Endocrinology 2008, 159:595-601.
63. Evans J.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., Morris A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330:1304-1305.
64. Fagan D.H., Uselman R.R., Sachdev D., Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: Implications for breast cancer treatment. Cancer Research 2012, 72:3372-3380.
65. Fagan D.H., Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. Journal of Mammary Gland Biology and Neoplasia 2008, 13:423-429.
66. Ferguson R.D., Novosyadlyy R., Fierz Y., Alikhani N., Sun H., Yakar S., et al. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Research 2012, 14:R8.
67. Fernandez A.M., Kim J.K., Yakar S., Dupont J., Hernandez-Sanchez C., Castle A.L., et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes & Development 2001, 15:1926-1934.
68. Fierz Y., Novosyadlyy R., Vijayakumar A., Yakar S., LeRoith D. Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes 2010, 59:686-693.
69. Fisher P.B., Goldstein N.I., Bonner D.P., Mechlinski W., Bryson V., Schaffner C.P. Toxicity of amphotericin B and its methyl ester toward normal and tumor cell lines. Cancer Research 1975, 35:1996-1999.
70. Flick E.D., Habel L.A., Chan K.A., Van Den Eeden S.K., Quinn V.P., Haque R., et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2007, 16:2218-2225.
71. Formica V., Tesauro M., Cardillo C., Roselli M. Insulinemia and the risk of breast cancer and its relapse. Diabetes, Obesity & Metabolism 2012.
72. Frasca F., Pandini G., Scalia P., Sciacca L., Mineo R., Costantino A., et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Molecular and Cellular Biology 1999, 19:3278-3288.
73. Freeman M.R., Solomon K.R. Cholesterol and prostate cancer. Journal of Cellular Biochemistry 2004, 91:54-69.
74. Freeman M.R., Solomon K.R., Moyad M. Statins and the risk of cancer. JAMA: The Journal of the American Medical Association 2006, 295:2720-2721. (author reply 2721-2722).
75. Frittitta L., Cerrato A., Sacco M.G., Weidner N., Goldfine I.D., Vigneri R. The insulin receptor content is increased in breast cancers initiated by three different oncogenes in transgenic mice. Breast Cancer Research and Treatment 1997, 45:141-147.
76. Frittitta L., Vigneri R., Papa V., Goldfine I.D., Grasso G., Trischitta V. Structural and functional studies of insulin receptors in human breast cancer. Breast Cancer Research and Treatment 1993, 25:73-82.
77. Fujita T., Sugiyama Y., Taketomi S., Sohda T., Kawamatsu Y., Iwatsuka H., et al. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 1983, 32:804-810.
78. Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., Horikoshi H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988, 37:1549-1558.
79. Furberg A.S., Jasienska G., Bjurstam N., Torjesen P.A., Emaus A., Lipson S.F., et al. Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiology, Biomarkers & Prevention 2005, 14:33-40.
80. Furberg A.S., Veierod M.B., Wilsgaard T., Bernstein L., Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. Journal of the National Cancer Institute 2004, 96:1152-1160.
81. Gal D., MacDonald P.C., Porter J.C., Simpson E.R. Cholesterol metabolism in cancer cells in monolayer culture. III. Low-density lipoprotein metabolism. International Journal of Cancer 1981, 28:315-319.
82. Gao J., Chesebrough J.W., Cartlidge S.A., Ricketts S.A., Incognito L., Veldman-Jones M., et al. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Research 2011, 71:1029-1040.
83. Garcia-Arencibia M., Molero S., Davila N., Carranza M.C., Calle C. 17beta-Estradiol transcriptionally represses human insulin receptor gene expression causing cellular insulin resistance. Leukemia Research 2005, 29:79-87.
84. Germershausen J.I., Hunt V.M., Bostedor R.G., Bailey P.J., Karkas J.D., Alberts A.W. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochemical and Biophysical Research Communications 1989, 158:667-675.
85. Gerstein H.C., Bosch J., Dagenais G.R., Diaz R., Jung H., Maggioni A.P., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. The New England Journal of Medicine 2012, 367:319-328.
86. Giani C., Campani D., Rasmussen A., Fierabracci P., Miccoli P., Bevilacqua G., et al. Insulin-like growth factor II (IGF-II) immunohistochemistry in breast cancer: Relationship with the most important morphological and biochemical prognostic parameters. The International Journal of Biological Markers 2002, 17:90-95.
87. Giani C., Cullen K.J., Campani D., Rasmussen A. IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: An in situ hybridization and immunohistochemistry study. Breast Cancer Research and Treatment 1996, 41:43-50.
88. Gingras A.C., Raught B., Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes & Development 2001, 15:807-826.
89. Giudice J., Leskow F.C., Arndt-Jovin D.J., Jovin T.M., Jares-Erijman E.A. Differential endocytosis and signaling dynamics of insulin receptor variants IR-A and IR-B. Journal of Cell Science 2011, 124:801-811.
90. Glidden E.J., Gray L.G., Vemuru S., Li D., Harris T.E., Mayo M.W. Multiple site acetylation of Rictor stimulates mammalian target of rapamycin complex 2 (mTORC2)-dependent phosphorylation of Akt protein. The Journal of Biological Chemistry 2012, 287:581-588.
91. Goetsch L., Gonzalez A., Leger O., Beck A., Pauwels P.J., Haeuw J.F., et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. International Journal of Cancer 2005, 113:316-328.
92. Gonzalez E., McGraw T.E. The Akt kinases: Isoform specificity in metabolism and cancer. Cell Cycle 2009, 8:2502-2508.
93. Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M.E., Koo J., Madarnas Y., et al. Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. Journal of Clinical Oncology 2002, 20:42-51.
94. Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M.E., Koo J., Taylor S.K., et al. Insulin- and obesity-related variables in early-stage breast cancer: Correlations and time course of prognostic associations. Journal of Clinical Oncology 2012, 30:164-171.
95. Gordon H.W., Schaffner C.P. The effect of polyene macrolides on the prostate gland and canine prostatic hyperplasia. Proceedings of the National Academy of Sciences of the United States of America 1968, 60:1201-1208.
96. Graaf M.R., Beiderbeck A.B., Egberts A.C., Richel D.J., Guchelaar H.J. The risk of cancer in users of statins. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2004, 22:2388-2394.
97. Graziani S.R., Igreja F.A., Hegg R., Meneghetti C., Brandizzi L.I., Barboza R., et al. Uptake of a cholesterol-rich emulsion by breast cancer. Gynecologic Oncology 2002, 85:493-497.
98. Gunter M.J., Hoover D.R., Yu H., Wassertheil-Smoller S., Rohan T.E., Manson J.E., et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute 2009, 101:48-60.
99. Hankinson S.E., Hunter D.J. Breast cancer. Textbook of cancer epidemiology 2002, 301-339. Oxford University Press, New York, NY. H.O. Adami, D. Hunter, D. Trichopoulos (Eds.).
100. Harrington S.C., Weroha S.J., Reynolds C., Suman V.J., Lingle W.L., Haluska P. Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Hormone & IGF Research 2012, 22:108-115.
101. Haruta T., Uno T., Kawahara J., Takano A., Egawa K., Sharma P.M., et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Molecular Endocrinology 2000, 14:783-794.
102. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes & Development 2004, 18:1926-1945.
103. He X., Esteva F.J., Ensor J., Hortobagyi G.N., Lee M.H., Yeung S.C. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Annals of Oncology 2012, 23:1771-1780.
104. He L., Sabet A., Djedjos S., Miller R., Sun X., Hussain M.A., et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009, 137:635-646.
105. Heemers H., Maes B., Foufelle F., Heyns W., Verhoeven G., Swinnen J.V. Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Molecular Endocrinology 2001, 15:1817-1828.
106. Hemkens L.G., Bender R., Grouven U., Sawicki P.T. Insulin glargine and cancer. Lancet 2009, 374:1743-1744. (author reply 1744).
107. Hemkens L.G., Grouven U., Bender R., Gunster C., Gutschmidt S., Selke G.W., et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia 2009, 52:1732-1744.
108. Hendrickson A.W., Haluska P. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy. Current Opinion in Investigational Drugs 2009, 10:1032-1040.
109. Henriksson P., Eriksson M., Ericsson S., Rudling M., Stege R., Berglund L., et al. Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate. Lancet 1989, 2:1178-1180.
110. Hou Z., He L., Qi R.Z. Regulation of s6 kinase 1 activation by phosphorylation at ser-411. The Journal of Biological Chemistry 2007, 282:6922-6928.
111. Huang J., Morehouse C., Streicher K., Higgs B.W., Gao J., Czapiga M., et al. Altered expression of insulin receptor isoforms in breast cancer. PLoS One 2011, 6:e26177.
112. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Molecular and Cellular Biology 2002, 22:7004-7014.
113. Hundal R.S., Krssak M., Dufour S., Laurent D., Lebon V., Chandramouli V., et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000, 49:2063-2069.
114. Huxley R. The impact of modifiable risk factors on mortality from prostate cancer in populations of the Asia-Pacific region. Asian Pacific Journal of Cancer Prevention 2007, 8:199-205.
115. Irwin M.L., Duggan C., Wang C.Y., Smith A.W., McTiernan A., Baumgartner R.N., et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: The health, eating, activity, and lifestyle study. Journal of Clinical Oncology 2011, 29:47-53.
116. Jonasson J.M., Ljung R., Talback M., Haglund B., Gudbjornsdottir S., Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009, 52:1745-1754.
117. Jones B.A., Kasl S.V., Howe C.L., Lachman M., Dubrow R., Curnen M.M., et al. African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 2004, 101:1293-1301.
118. Juurinen L., Kotronen A., Graner M., Yki-Jarvinen H. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. The Journal of Clinical Endocrinology and Metabolism 2008, 93:118-124.
119. Kalla Singh S., Brito C., Tan Q.W., De Leon M., De Leon D. Differential expression and signaling activation of insulin receptor isoforms A and B: A link between breast cancer and diabetes. Growth Factors 2011, 29:278-289.
120. Kaplan S.A. The insulin receptor. The Journal of Pediatrics 1984, 104:327-336.
121. Kaplan M.A., Pekkolay Z., Kucukoner M., Inal A., Urakci Z., Ertugrul H., et al. Type 2 diabetes mellitus and prognosis in early stage breast cancer women. Medical Oncology 2012, 29:1576-1580.
122. Kaulsay K.K., Ng E.H., Ji C.Y., Ho G.H., Aw T.C., Lee K.O. Serum IGF-binding protein-6 and prostate specific antigen in breast cancer. European Journal of Endocrinology 1999, 140:164-168.
123. Kelly M.J., Levin E.R. Rapid actions of plasma membrane estrogen receptors. Trends in Endocrinology and Metabolism 2001, 12:152-156.
124. Keshin J.G. Effect of candicidin on the human benign hypertrophied prostate gland. International Surgery 1973, 58:116-122.
125. Key T.J., Appleby P.N., Reeves G.K., Roddam A., Dorgan J.F., Longcope C., et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. Journal of the National Cancer Institute 2003, 95:1218-1226.
126. Keys A., Aravanis C., Blackburn H., Buzina R., Dontas A.S., Fidanza F., et al. Serum cholesterol and cancer mortality in the Seven Countries Study. American Journal of Epidemiology 1985, 121:870-883.
127. Kiely P.A., O'Gorman D., Luong K., Ron D., O'Connor R. Insulin-like growth factor I controls a mutually exclusive association of RACK1 with protein phosphatase 2A and beta1 integrin to promote cell migration. Molecular and Cellular Biology 2006, 26:4041-4051.
128. Kim Y.D., Park K.G., Lee Y.S., Park Y.Y., Kim D.K., Nedumaran B., et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 2008, 57:306-314.
129. Kirschner M.A., Schneider G., Ertel N.H., Worton E. Obesity, androgens, estrogens, and cancer risk. Cancer Research 1982, 42:3281s-3285s.
130. Kitamura T., Kitamura Y., Kuroda S., Hino Y., Ando M., Kotani K., et al. Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Molecular and Cellular Biology 1999, 19:6286-6296.
131. Koga T., Shimada Y., Kuroda M., Tsujita Y., Hasegawa K., Yamazaki M. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochimica et Biophysica Acta 1990, 1045:115-120.
132. Kok D.E., van Roermund J.G., Aben K.K., den Heijer M., Swinkels D.W., Kampman E., et al. Blood lipid levels and prostate cancer risk; a cohort study. Prostate Cancer and Prostatic Diseases 2011, 14:340-345.
133. Kolanjiappan K., Ramachandran C.R., Manoharan S. Biochemical changes in tumor tissues of oral cancer patients. Clinical Biochemistry 2003, 36:61-65.
134. Koo S.H., Flechner L., Qi L., Zhang X., Screaton R.A., Jeffries S., et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005, 437:1109-1111.
135. Kopelman P.G., Pilkington T.R., White N., Jeffcoate S.L. Abnormal sex steroid secretion and binding in massively obese women. Clinical Endocrinology 1980, 12:363-369.
136. Kucharska-Newton A.M., Rosamond W.D., Mink P.J., Alberg A.J., Shahar E., Folsom A.R. HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Annals of Epidemiology 2008, 18:671-677.
137. Landman G.W., Kleefstra N., van Hateren K.J., Groenier K.H., Gans R.O., Bilo H.J. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010, 33:322-326.
138. Larsson S.C., Mantzoros C.S., Wolk A. Diabetes mellitus and risk of breast cancer: A meta-analysis. International Journal of Cancer 2007, 121:856-862.
139. Law J.H., Habibi G., Hu K., Masoudi H., Wang M.Y., Stratford A.L., et al. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Research 2008, 68:10238-10246.
140. Lawson K.A., Anderson K., Menchaca M., Atkinson J., Sun L., Knight V., et al. Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis. Molecular Cancer Therapeutics 2003, 2:437-444.
141. Le T.N., Nestler J.E., Strauss J.F., Wickham E.P. Sex hormone-binding globulin and type 2 diabetes mellitus. Trends in Endocrinology and Metabolism 2012, 23:32-40.
142. Lee C.W., Hong D.H., Han S.B., Jung S.H., Kim H.C., Fine R.L., et al. A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-on e, has antitumor efficacy in in vitro and in vivo tumor models. Biochemical Pharmacology 2002, 64:473-480.
143. Lee A.V., Jackson J.G., Gooch J.L., Hilsenbeck S.G., Coronado-Heinsohn E., Osborne C.K., et al. Enhancement of insulin-like growth factor signaling in human breast cancer: Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Molecular Endocrinology 1999, 13:787-796.
144. Leung Y.K., Lee M.T., Lam H.M., Tarapore P., Ho S.M. Estrogen receptor-beta and breast cancer: Translating biology into clinical practice. Steroids 2012, 77:727-737.
145. Levine A.J., Puzio-Kuter A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330:1340-1344.
146. Lewis J.D., Ferrara A., Peng T., Hedderson M., Bilker W.B., Quesenberry C.P., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011, 34:916-922.
147. Li B.D., Liu L., Dawson M., De Benedetti A. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 1997, 79:2385-2390.
148. Li B.D., McDonald J.C., Nassar R., De Benedetti A. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Annals of Surgery 1998, 227:756-761. (discussion 761-763).
149. Li X., Monks B., Ge Q., Birnbaum M.J. Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature 2007, 447:1012-1016.
150. Li Y.C., Park M.J., Ye S.K., Kim C.W., Kim Y.N. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. The American Journal of Pathology 2006, 168:1107-1118. (quiz 1404-1405).
151. Lind M., Fahlen M., Eliasson B., Oden A. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Primary Care Diabetes 2012, 6:53-59.
152. Lisztwan J., Pornon A., Chen B., Chen S., Evans D.B. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Research 2008, 10:R56.
153. Liu B.L., Fan Z.Y., Edgerton S.M., Deng X.S., Alimova I.N., Lind S.E., et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009, 8:2031-2040.
154. Liu Y.L., Qian H.X., Qin L., Zhou X.J., Zhang B., Chen X. Association of serum lipid profile with distant metastasis in breast cancer patients. Zhonghua Zhong Liu Za Zhi 2012, 34:129-131.
155. Ljung R., Talback M., Haglund B., Jonasson J.M., Gudbjornsdottir S., Steineck G. Insulin glargine use and short-term incidence of breast cancer-A four-year population-based observation. Acta Oncologica 2012, 51:400-402.
156. Lynch L., Vodyanik P.I., Boettiger D., Guvakova M.A. Insulin-like growth factor I controls adhesion strength mediated by alpha5beta1 integrins in motile carcinoma cells. Molecular Biology of the Cell 2005, 16:51-63.
157. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. The Journal of Biological Chemistry 1998, 273:13375-13378.
158. Magura L., Blanchard R., Hope B., Beal J.R., Schwartz G.G., Sahmoun A.E. Hypercholesterolemia and prostate cancer: A hospital-based case-control study. Cancer Causes & Control 2008, 19:1259-1266.
159. Mainous A.G., Wells B.J., Koopman R.J., Everett C.J., Gill J.M. Iron, lipids, and risk of cancer in the Framingham Offspring cohort. American Journal of Epidemiology 2005, 161:1115-1122.
160. Malaguarnera R., Sacco A., Voci C., Pandini G., Vigneri R., Belfiore A. Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinology 2012, 153:2152-2163.
161. Malik S., Jiang S., Garee J.P., Verdin E., Lee A.V., O'Malley B.W., et al. Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM. Molecular and Cellular Biology 2010, 30:399-412.
162. Mamillapalli R., Gavrilova N., Mihaylova V.T., Tsvetkov L.M., Wu H., Zhang H., et al. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Current Biology 2001, 11:263-267.
163. Mamtani R., Haynes K., Bilker W.B., Vaughn D.J., Strom B.L., Glanz K., et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: A cohort study. Journal of the National Cancer Institute 2012, 104:1411-1421.
164. Marshman E., Streuli C.H. Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Research 2002, 4:231-239.
165. Mayer D., Chantelau E. Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: A pilot study on MCF-7 breast cancer cells. Archives of Physiology and Biochemistry 2010, 116:73-78.
166. Mayer D., Shukla A., Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Archives of Physiology and Biochemistry 2008, 114:38-44.
167. McCann A.H., Miller N., O'Meara A., Pedersen I., Keogh K., Gorey T., et al. Biallelic expression of the IGF2 gene in human breast disease. Human Molecular Genetics 1996, 5:1123-1127.
168. McInnes K.J., Brown K.A., Hunger N.I., Simpson E.R. Regulation of LKB1 expression by sex hormones in adipocytes. International Journal of Obesity 2011, 36:982-985.
169. Mehta N., Hordines J., Volpe C., Doerr R., Cohen S.A. Cellular effects of hypercholesterolemia in modulation of cancer growth and metastasis: A review of the evidence. Surgical Oncology 1997, 6:179-185.
170. Meirow D., Yossepowitch O., Rosler A., Brzezinski A., Schenker J.G., Laufer N., et al. Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups. Human Reproduction 1995, 10:1951-1956.
171. Menrad A., Anderer F.A. Expression of LDL receptor on tumor cells induced by growth factors. Anticancer Research 1991, 11:385-390.
172. Miller T.W., Perez-Torres M., Narasanna A., Guix M., Stal O., Perez-Tenorio G., et al. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Research 2009, 69:4192-4201.
173. Miraglia E., Hogberg J., Stenius U. Statins exhibit anticancer effects through modifications of the pAkt signaling pathway. International Journal of Oncology 2012, 40:867-875.
174. Miyazaki Y., Mahankali A., Matsuda M., Mahankali S., Hardies J., Cusi K., et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. The Journal of Clinical Endocrinology and Metabolism 2002, 87:2784-2791.
175. Moller D.E., Yokota A., Caro J.F., Flier J.S. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Molecular Endocrinology 1989, 3:1263-1269.
176. Molloy C.A., May F.E., Westley B.R. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. The Journal of Biological Chemistry 2000, 275:12565-12571.
177. Monami M., Balzi D., Lamanna C., Barchielli A., Masotti G., Buiatti E., et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes/Metabolism Research and Reviews 2007, 23:479-484.
178. Monami M., Lamanna C., Balzi D., Marchionni N., Mannucci E. Sulphonylureas and cancer: A case-control study. Acta Diabetologica 2009, 46:279-284.
179. Mondul A.M., Clipp S.L., Helzlsouer K.J., Platz E.A. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes & Control 2010, 21:61-68.
180. Mondul A.M., Weinstein S.J., Virtamo J., Albanes D. Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes & Control 2011, 22:1545-1552.
181. Monetti M., Canavesi M., Camera M., Parente R., Paoletti R., Tremoli E., et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacological Research: The Official Journal of the Italian Pharmacological Society 2007, 55:441-449.
182. Morris P.G., Hudis C.A., Giri D., Morrow M., Falcone D.J., Zhou X.K., et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prevention Research (Philadelphia, PA) 2011, 4:1021-1029.
183. Mostaghel E.A., Solomon K.R., Pelton K., Freeman M.R., Montgomery R.B. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One 2012, 7:e30062.
184. Mosthaf L., Grako K., Dull T.J., Coussens L., Ullrich A., McClain D.A. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. The EMBO Journal 1990, 9:2409-2413.
185. Muoio D.M., Newgard C.B. Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nature Reviews. Molecular Cell Biology 2008, 9:193-205.
186. Murtola T.J., Tammela T.L., Lahtela J., Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: A population-based case-control study. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2007, 16:2226-2232.
187. Musgrove E.A., Sutherland R.L. Biological determinants of endocrine resistance in breast cancer. Nature Reviews. Cancer 2009, 9:631-643.
188. Nichols H.B., Trentham-Dietz A., Egan K.M., Titus-Ernstoff L., Holmes M.D., Bersch A.J., et al. Body mass index before and after breast cancer diagnosis: Associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiology, Biomarkers & Prevention 2009, 18:1403-1409.
189. Novosyadlyy R., Lann D.E., Vijayakumar A., Rowzee A., Lazzarino D.A., Fierz Y., et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Research 2010, 70:741-751.
190. Novosyadlyy R., Vijayakumar A., Lann D., Fierz Y., Kurshan N., LeRoith D. Physical and functional interaction between polyoma virus middle T antigen and insulin and IGF-I receptors is required for oncogene activation and tumour initiation. Oncogene 2009, 28:3477-3486.
191. Orkin L.A. Efficacy of candicidin in benign prostatic hypertrophy. Urology 1974, 4:80-84.
192. Ormandy C.J., Musgrove E.A., Hui R., Daly R.J., Sutherland R.L. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Research and Treatment 2003, 78:323-335.
193. Osborne C.K., Monaco M.E., Lippman M.E., Kahn C.R. Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Research 1978, 38:94-102.
194. Owen M.R., Doran E., Halestrap A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. The Biochemical Journal 2000, 348(Pt 3):607-614.
195. Ozacmak V.H., Sayan H., Igdem A.A., Cetin A., Ozacmak I.D. Attenuation of contractile dysfunction by atorvastatin after intestinal ischemia reperfusion injury in rats. European Journal of Pharmacology 2007, 562:138-147.
196. Papa V., Pezzino V., Costantino A., Belfiore A., Giuffrida D., Frittitta L., et al. Elevated insulin receptor content in human breast cancer. The Journal of Clinical Investigation 1990, 86:1503-1510.
197. Pasquali R., Casimirri F., Cantobelli S., Melchionda N., Morselli Labate A.M., Fabbri R., et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 1991, 40:101-104.
198. Pasqualini J.R., Chetrite G.S. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. The Journal of Steroid Biochemistry and Molecular Biology 2005, 93:221-236.
199. Peairs K.S., Barone B.B., Snyder C.F., Yeh H.C., Stein K.B., Derr R.L., et al. Diabetes mellitus and breast cancer outcomes: A systematic review and meta-analysis. Journal of Clinical Oncology 2011, 29:40-46.
200. Pearce S.T., Jordan V.C. The biological role of estrogen receptors alpha and beta in cancer. Critical Reviews in Oncology/Hematology 2004, 50:3-22.
201. Periyasamy-Thandavan S., Takhar S., Singer A., Dohn M.R., Jackson W.H., Welborn A.E., et al. Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim. Breast Cancer Research 2012, 14:R52.
202. Phielix E., Szendroedi J., Roden M. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends in Pharmacological Sciences 2011, 32:607-616.
203. Pike M.C., Pearce C.L., Wu A.H. Prevention of cancers of the breast, endometrium and ovary. Oncogene 2004, 23:6379-6391.
204. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Archives of Physiology and Biochemistry 2008, 114:63-70.
205. Platz E.A., Clinton S.K., Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. International Journal of Cancer 2008, 123:1693-1698.
206. Platz E.A., Leitzmann M.F., Visvanathan K., Rimm E.B., Stampfer M.J., Willett W.C., et al. Statin drugs and risk of advanced prostate cancer. Journal of the National Cancer Institute 2006, 98:1819-1825.
207. Platz E.A., Till C., Goodman P.J., Parnes H.L., Figg W.D., Albanes D., et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2009, 18:2807-2813.
208. Pritchard K.I., Shepherd L.E., Chapman J.A., Norris B.D., Cantin J., Goss P.E., et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. Journal of Clinical Oncology 2011, 29:3869-3876.
209. Qian X., Li J., Ding J., Wang Z., Duan L., Hu G. Glibenclamide exerts an antitumor activity through reactive oxygen species-c-jun NH2-terminal kinase pathway in human gastric cancer cell line MGC-803. Biochemical Pharmacology 2008, 76:1705-1715.
210. Qiu J., Yang R., Rao Y., Du Y., Kalembo F.W. Risk factors for breast cancer and expression of insulin-like growth factor-2 (IGF-2) in women with breast cancer in Wuhan City, China. PLoS One 2012, 7:e36497.
211. Renehan A.G., Zwahlen M., Minder C., O'Dwyer S.T., Shalet S.M., Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet 2004, 363:1346-1353.
212. Rhoads R.P., Kim J.W., Leury B.J., Baumgard L.H., Segoale N., Frank S.J., et al. Insulin increases the abundance of the growth hormone receptor in liver and adipose tissue of periparturient dairy cows. The Journal of Nutrition 2004, 134:1020-1027.
213. Richardson A.E., Hamilton N., Davis W., Brito C., De Leon D. Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-alpha and -beta via the IGF-1 and the insulin receptors in breast cancer cells. Growth Factors 2011, 29:82-93.
214. Rinaldi S., Peeters P.H., Berrino F., Dossus L., Biessy C., Olsen A., et al. IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocrine-Related Cancer 2006, 13:593-605.
215. Rodenburg J., Vissers M.N., Wiegman A., van Trotsenburg A.S., van der Graaf A., de Groot E., et al. Statin treatment in children with familial hypercholesterolemia: The younger, the better. Circulation 2007, 116:664-668.
216. Rose D.P., Vona-Davis L. Influence of obesity on breast cancer receptor status and prognosis. Expert Review of Anticancer Therapy 2009, 9:1091-1101.
217. Rudling M.J., Angelin B., Peterson C.O., Collins V.P. Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. Cancer Research 1990, 50:483-487.
218. Rudling M., Collins V.P. Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordinately reduced in human renal cell carcinoma. Biochimica et Biophysica Acta 1996, 1299:75-79.
219. Sachdev D., Li S.L., Hartell J.S., Fujita-Yamaguchi Y., Miller J.S., Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Research 2003, 63:627-635.
220. Sachdev D., Yee D. The IGF system and breast cancer. Endocrine-Related Cancer 2001, 8:197-209.
221. Saez E., Rosenfeld J., Livolsi A., Olson P., Lombardo E., Nelson M., et al. PPAR gamma signaling exacerbates mammary gland tumor development. Genes & Development 2004, 18:528-540.
222. Salas T.R., Reddy S.A., Clifford J.L., Davis R.J., Kikuchi A., Lippman S.M., et al. Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei. The Journal of Biological Chemistry 2003, 278:41338-41346.
223. Saltiel A.R., Pessin J.E. Insulin signaling pathways in time and space. Trends in Cell Biology 2002, 12:65-71.
224. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Current Biology 2004, 14:1296-1302.
225. Sarbassov D.D., Ali S.M., Sabatini D.M. Growing roles for the mTOR pathway. Current Opinion in Cell Biology 2005, 17:596-603.
226. Schaffner C.P. Prostatic cholesterol metabolism: Regulation and alteration. Progress in Clinical and Biological Research 1981, 75A:279-324.
227. Schaffner C.P., Gordon H.W. The hypocholesterolemic activity of orally administered polyene macrolides. Proceedings of the National Academy of Sciences of the United States of America 1968, 61:36-41.
228. Schernhammer E.S., Holly J.M., Pollak M.N., Hankinson S.E. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiology, Biomarkers & Prevention 2005, 14:699-704.
229. Sciacca L., Costantino A., Pandini G., Mineo R., Frasca F., Scalia P., et al. Insulin receptor activation by IGF-II in breast cancers: Evidence for a new autocrine/paracrine mechanism. Oncogene 1999, 18:2471-2479.
230. Seino S., Bell G.I. Alternative splicing of human insulin receptor messenger RNA. Biochemical and Biophysical Research Communications 1989, 159:312-316.
231. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nature Reviews. Cancer 2009, 9:563-575.
232. Shannon J., Tewoderos S., Garzotto M., Beer T.M., Derenick R., Palma A., et al. Statins and prostate cancer risk: A case-control study. American Journal of Epidemiology 2005, 162:318-325.
233. Shen W.H., Yang X., Boyle D.W., Lee W.H., Liechty E.A. Effects of intravenous insulin-like growth factor-I and insulin administration on insulin-like growth factor-binding proteins in the ovine fetus. The Journal of Endocrinology 2001, 171:143-151.
234. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. The New England Journal of Medicine 1995, 333:1301-1307.
235. Simons K., Ikonen E. How cells handle cholesterol. Science 2000, 290:1721-1726.
236. Simpson E.R., Ackerman G.E., Smith M.E., Mendelson C.R. Estrogen formation in stromal cells of adipose tissue of women: Induction by glucocorticosteroids. Proceedings of the National Academy of Sciences of the United States of America 1981, 78:5690-5694.
237. Sirtori C.R. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacology & Therapeutics 1993, 60:431-459.
238. Slaaby R., Schaffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C., Mathiasen I.S., et al. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. The Journal of Biological Chemistry 2006, 281:25869-25874.
239. Solomon K.R., Freeman M.R. Do the cholesterol-lowering properties of statins affect cancer risk?. Trends in Endocrinology and Metabolism 2008, 19:113-121.
240. Spaventi R., Antica M., Pavelic K. Insulin and insulin-like growth factor I (IGF I) in early mouse embryogenesis. Development 1990, 108:491-495.
241. Sporer A., Cohen S., Kamat M.H., Seebode J.J. Candicidin: Physiologic effect on prostate. Urology 1975, 6:298-304.
242. Sridharan S., Basu A. S6 kinase 2 promotes breast cancer cell survival via Akt. Cancer Research 2011, 71:2590-2599.
243. Stopeck A.T., Nicholson A.C., Mancini F.P., Hajjar D.P. Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells. The Journal of Biological Chemistry 1993, 268:17489-17494.
244. Straus D.S., Glass C.K. Anti-inflammatory actions of PPAR ligands: New insights on cellular and molecular mechanisms. Trends in Immunology 2007, 28:551-558.
245. Subbaramaiah K., Howe L.R., Bhardwaj P., Du B., Gravaghi C., Yantiss R.K., et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prevention Research (Philadelphia, PA) 2011, 4:329-346.
246. Suissa S., Azoulay L., Dell'Aniello S., Evans M., Vora J., Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 2011, 54:2254-2262.
247. Suzuki T., Miki Y., Ohuchi N., Sasano H. Intratumoral estrogen production in breast carcinoma: Significance of aromatase. Breast Cancer 2008, 15:270-277.
248. Swyer G.I.M. The cholesterol content of normal and enlarged prostates. Cancer Research 1942, 2:372-375.
249. Tatidis L., Masquelier M., Vitols S. Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. Biochemical Pharmacology 2002, 63:2169-2180.
250. Tee A.R., Manning B.D., Roux P.P., Cantley L.C., Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Current Biology 2003, 13:1259-1268.
251. Tiikkainen M., Hakkinen A.M., Korsheninnikova E., Nyman T., Makimattila S., Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53:2169-2176.
252. Toniolo P.G., Levitz M., Zeleniuch-Jacquotte A., Banerjee S., Koenig K.L., Shore R.E., et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. Journal of the National Cancer Institute 1995, 87:190-197.
253. Toropainen E.M., Lipponen P.K., Syrjanen K.J. Expression of insulin-like growth factor II in female breast cancer as related to established prognostic factors and long-term prognosis. Anticancer Research 1995, 15:2669-2674.
254. Toschi A., Lee E., Gadir N., Ohh M., Foster D.A. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. The Journal of Biological Chemistry 2008, 283:34495-34499.
255. Tworoger S.S., Eliassen A.H., Kelesidis T., Colditz G.A., Willett W.C., Mantzoros C.S., et al. Plasma adiponectin concentrations and risk of incident breast cancer. The Journal of Clinical Endocrinology and Metabolism 2007, 92:1510-1516.
256. Uhles S., Moede T., Leibiger B., Berggren P.O., Leibiger I.B. Isoform-specific insulin receptor signaling involves different plasma membrane domains. The Journal of Cell Biology 2003, 163:1327-1337.
257. Ulanet D.B., Ludwig D.L., Kahn C.R., Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:10791-10798.
258. van Landeghem A.A., Poortman J., Nabuurs M., Thijssen J.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Research 1985, 45:2900-2906.
259. Vitols S., Norgren S., Juliusson G., Tatidis L., Luthman H. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood 1994, 84:2689-2698.
260. Wadsack C., Hrzenjak A., Hammer A., Hirschmugl B., Levak-Frank S., Desoye G., et al. Trophoblast-like human choriocarcinoma cells serve as a suitable in vitro model for selective cholesteryl ester uptake from high density lipoproteins. European Journal of Biochemistry/FEBS 2003, 270:451-462.
261. Webster N.J., Resnik J.L., Reichart D.B., Strauss B., Haas M., Seely B.L. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: A possible mechanism for receptor overexpression in breast cancer. Cancer Research 1996, 56:2781-2788.
262. Weinstein D., Simon M., Yehezkel E., Laron Z., Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes/Metabolism Research and Reviews 2009, 25:41-49.
263. Weng L., Brown J., Eng C. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Human Molecular Genetics 2001, 10:237-242.
264. Weng L.P., Smith W.M., Brown J.L., Eng C. PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Human Molecular Genetics 2001, 10:605-616.
265. Wolf I., Sadetzki S., Catane R., Karasik A., Kaufman B. Diabetes mellitus and breast cancer. The Lancet Oncology 2005, 6:103-111.
266. Wondergem R., Cregan M., Strickler L., Miller R., Suttles J. Membrane potassium channels and human bladder tumor cells: II. Growth properties. The Journal of Membrane Biology 1998, 161:257-262.
267. Wu M.H., Chou Y.C., Chou W.Y., Hsu G.C., Chu C.H., Yu C.P., et al. Circulating levels of leptin, adiposity and breast cancer risk. British Journal of Cancer 2009, 100:578-582.
268. Xu J., Chen Y., Olopade O.I. MYC and breast cancer. Genes & Cancer 2010, 1:629-640.
269. Xue F., Michels K.B. Diabetes, metabolic syndrome, and breast cancer: A review of the current evidence. The American Journal of Clinical Nutrition 2007, 86:s823-s835.
270. Yager J.D., Davidson N.E. Estrogen carcinogenesis in breast cancer. The New England Journal of Medicine 2006, 354:270-282.
271. Yamaguchi Y., Flier J.S., Benecke H., Ransil B.J., Moller D.E. Ligand-binding properties of the two isoforms of the human insulin receptor. Endocrinology 1993, 132:1132-1138.
272. Yamnik R.L., Digilova A., Davis D.C., Brodt Z.N., Murphy C.J., Holz M.K. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. The Journal of Biological Chemistry 2009, 284:6361-6369.
273. Yang S.H., Liu R., Perez E.J., Wen Y., Stevens S.M., Valencia T., et al. Mitochondrial localization of estrogen receptor beta. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:4130-4135.
274. Yee D., Paik S., Lebovic G.S., Marcus R.R., Favoni R.E., Cullen K.J., et al. Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer. Molecular Endocrinology 1989, 3:509-517.
275. Yoshioka Y., Sasaki J., Yamamoto M., Saitoh K., Nakaya S., Kubokawa M. Quantitation by (1)H-NMR of dolichol, cholesterol and choline-containing lipids in extracts of normal and phathological thyroid tissue. NMR in Biomedicine 2000, 13:377-383.
276. Yu H., Jin F., Shu X.O., Li B.D., Dai Q., Cheng J.R., et al. Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiology, Biomarkers & Prevention 2002, 11:705-712.
277. Zakikhani M., Blouin M.J., Piura E., Pollak M.N. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Research and Treatment 2010, 123:271-279.
278. Zakikhani M., Dowling R., Fantus I.G., Sonenberg N., Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Research 2006, 66:10269-10273.
279. Zhang H., Fagan D.H., Zeng X., Freeman K.T., Sachdev D., Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 2010, 29:2517-2527.
280. Zhang Y., Moerkens M., Ramaiahgari S., de Bont H., Price L., Meerman J., et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Research 2011, 13:R52.
281. Zhou D., Clarke P., Wang J., Chen S. Identification of a promoter that controls aromatase expression in human breast cancer and adipose stromal cells. The Journal of Biological Chemistry 1996, 271:15194-15202.
282. Zhou S., Wang G.P., Liu C., Zhou M. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: Prognostic markers for breast cancer. BMC Cancer 2006, 6:231.
283. Zhu C., Qi X., Chen Y., Sun B., Dai Y., Gu Y. PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer. Journal of Cancer Research and Clinical Oncology 2011, 137:1587-1594.